Whilst Britain bunkers down in preparation for the so called Swine Flu "pandemic", GlaxoSmithKline hopes to reap the benefit of 18 years of preparation by generating £600M from its Relenza treatment this year.
The British Government has ordered 132 million doses from GSK and Baxter, an American company.
Quite what the profit margin GSK makes on a dose of Relenza is unclear. The company have dismissed rumours that it plans to sell it at £6 a dose, compared to £1 a dose manufacturing cost.
Doubtless our "economically astute" government has negotiated a "good" price!